AI Engines For more Details: Perplexity Kagi Labs You
Alpha-1 Blocker: Alfuzosin hydrochloride belongs to a class of medications known as alpha-1 adrenergic blockers. It works by selectively blocking alpha-1 adrenergic receptors in the smooth muscle of the prostate gland, bladder neck, and urethra. This results in relaxation of the smooth muscle, leading to improved urine flow and reduced symptoms of BPH.
Symptom Relief in BPH: Alfuzosin hydrochloride is indicated for the relief of symptoms associated with BPH, including urinary hesitancy, weak stream, incomplete bladder emptying, nocturia (nighttime urination), and urinary urgency or frequency.
Improvement in Urinary Flow: By reducing the constriction of the prostate gland and bladder neck, alfuzosin hydrochloride helps improve urinary flow rate and reduce the sensation of incomplete bladder emptying. This can lead to decreased urinary symptoms and improved quality of life in patients with BPH.
Dose and Administration: Alfuzosin hydrochloride is typically administered orally as an extended-release tablet, usually once daily with food. The extended-release formulation allows for consistent drug levels in the body and may help minimize side effects such as dizziness or orthostatic hypotension.
Treatment Duration: Alfuzosin hydrochloride is often prescribed as a long-term treatment for BPH to provide ongoing symptom relief and prevent disease progression. It may take several weeks to months for patients to experience maximal improvement in urinary symptoms.
Effect on Blood Pressure: Alfuzosin hydrochloride can cause orthostatic hypotension, a sudden drop in blood pressure upon standing up from a sitting or lying position. Patients should be advised to change positions slowly to minimize the risk of dizziness or fainting, particularly during the initiation of therapy or dose adjustments.
Contraindications: Alfuzosin hydrochloride is contraindicated in patients with a known hypersensitivity to the drug or its components, as well as those with severe hepatic impairment, orthostatic hypotension, or a history of priapism (prolonged erection).
Drug Interactions: Alfuzosin hydrochloride may interact with certain medications, including other alpha-blockers, antihypertensive drugs, and phosphodiesterase-5 inhibitors (such as sildenafil or tadalafil). Concomitant use of these medications may increase the risk of hypotension or other adverse effects.
Cataract Surgery: Patients taking alfuzosin hydrochloride should inform their ophthalmologist if they are scheduled for cataract surgery. Alpha-blockers, including alfuzosin, can cause intraoperative floppy iris syndrome (IFIS), a complication that may increase the risk of complications during cataract surgery.
Side Effects: Common side effects of alfuzosin hydrochloride may include dizziness, headache, fatigue, nasal congestion, and gastrointestinal symptoms such as nausea or diarrhea. These side effects are usually mild and transient and may resolve with continued use or dose adjustments.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 1.4 | 0.3 | 3.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.3 | 1 |
| Allergies | 0.6 | 1.2 | -1 |
| Allergy to milk products | 0.9 | 0.3 | 2 |
| Alzheimer's disease | 1 | 1.8 | -0.8 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 0.6 | 0.9 | -0.5 |
| Anorexia Nervosa | 0.6 | 1.4 | -1.33 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 1.7 | 1.1 | 0.55 |
| Atherosclerosis | 0.9 | 0.7 | 0.29 |
| Atrial fibrillation | 1.2 | 0.3 | 3 |
| Autism | 2.1 | 2 | 0.05 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 0.6 | 1.1 | -0.83 |
| Brain Trauma | 0.3 | 1.1 | -2.67 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.3 | 0.6 | -1 |
| Carcinoma | 1.3 | 0.6 | 1.17 |
| Celiac Disease | 0.7 | 0.6 | 0.17 |
| Cerebral Palsy | 0.6 | 1.1 | -0.83 |
| Chronic Fatigue Syndrome | 1.7 | 1.8 | -0.06 |
| Chronic Kidney Disease | 0.3 | 0.8 | -1.67 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.4 | -0.17 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1.1 | -2.67 |
| Cognitive Function | 0.9 | 0.8 | 0.13 |
| Colorectal Cancer | 2.2 | 0.8 | 1.75 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 0.6 | 1.1 | -0.83 |
| COVID-19 | 1.2 | 2.5 | -1.08 |
| Crohn's Disease | 2.2 | 1.7 | 0.29 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.5 | 1.4 | -1.8 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 2.7 | 3 | -0.11 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 0.6 | 0 |
| Endometriosis | 0.9 | 1.1 | -0.22 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 0.9 | 0.3 | 2 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 0.5 | 0.9 | -0.8 |
| Functional constipation / chronic idiopathic constipation | 1.3 | 1.4 | -0.08 |
| gallstone disease (gsd) | 0.3 | 0.8 | -1.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.3 | 0.67 |
| Generalized anxiety disorder | 1.2 | 0.9 | 0.33 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1 | 0.3 | 2.33 |
| Graves' disease | 0.6 | 1.4 | -1.33 |
| Gulf War Syndrome | 0.6 | 0.6 | |
| Halitosis | 1 | 0.3 | 2.33 |
| Hashimoto's thyroiditis | 1.4 | 0.3 | 3.67 |
| Heart Failure | 1.3 | 0.8 | 0.63 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hyperglycemia | 0.3 | 0.3 | 0 |
| hypertension (High Blood Pressure | 0.9 | 1.7 | -0.89 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 1.2 | 0.5 | 1.4 |
| Inflammatory Bowel Disease | 1.3 | 2.5 | -0.92 |
| Insomnia | 1.2 | 1.4 | -0.17 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.9 | 0.3 | 2 |
| Irritable Bowel Syndrome | 1.6 | 1.7 | -0.06 |
| ischemic stroke | 0.9 | 0.8 | 0.13 |
| Liver Cirrhosis | 2.3 | 2 | 0.15 |
| Long COVID | 1.6 | 2.1 | -0.31 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.5 | 0.6 | -0.2 |
| ME/CFS with IBS | 0.4 | 0.9 | -1.25 |
| ME/CFS without IBS | 0.3 | 0.3 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 2 | 2 | 0 |
| Mood Disorders | 2.7 | 2.9 | -0.07 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 1.2 | 1.7 | -0.42 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.8 | -0.8 | |
| Neuropathy (all types) | 0.3 | 0.5 | -0.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 1.4 | 0.21 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 2 | 3.1 | -0.55 |
| obsessive-compulsive disorder | 0.9 | 0.9 | 0 |
| Osteoarthritis | 0.6 | 0.9 | -0.5 |
| Osteoporosis | 1.1 | 0.6 | 0.83 |
| pancreatic cancer | 0.5 | 0.3 | 0.67 |
| Parkinson's Disease | 2.1 | 2.1 | 0 |
| Polycystic ovary syndrome | 2.4 | 1.8 | 0.33 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 0.9 | 0.6 | 0.5 |
| Psoriasis | 0.6 | 1.1 | -0.83 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.2 | 1.4 | 0.57 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 1.5 | 1.4 | 0.07 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 0.3 | 0.3 | 0 |
| Sleep Apnea | 0.9 | 1.4 | -0.56 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1.2 | |
| Stress / posttraumatic stress disorder | 1.1 | 1.1 | 0 |
| Systemic Lupus Erythematosus | 1.2 | 0.8 | 0.5 |
| Tic Disorder | 0.6 | 0.6 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.2 | 1.4 | -0.17 |
| Type 2 Diabetes | 2.1 | 2 | 0.05 |
| Ulcerative colitis | 0.8 | 1.4 | -0.75 |
| Unhealthy Ageing | 1.4 | 0.8 | 0.75 |
| Vitiligo | 0.9 | 0.6 | 0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
